Quantcast

Latest Triptorelin Stories

2010-05-03 10:37:00

Preliminary review suggests an increase in the risk of diabetes and certain cardiovascular diseases in men treated with GnRH agonists SILVER SPRING, Md., May 3 /PRNewswire-USNewswire/ -- Gonadotropin-Releasing Hormone (GnRH) agonists, a class of medications primarily used to treat men with prostate cancer, have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing...

2010-03-11 15:15:00

MORRISTOWN, N.J., March 11 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced the U.S.

2010-02-04 00:30:00

PARIS and LAUSANNE, Switzerland, February 4 /PRNewswire/ -- Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22.5 mg 6-month sustained-release formulation for the treatment of locally advanced or metastatic...

2009-10-13 00:30:00

LAUSANNE, Switzerland and PARIS, October 13 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical Group, announced that the 6-month sustained-release formulation of Decapeptyl(R)[1] (triptorelin embonate[2] 22.5 mg) successfully completed its European decentralised...

2009-07-21 04:18:00

LAUSANNE, Switzerland, July 21 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that the Swiss agency for therapeutic products, Swissmedic, has issued a marketing authorisation for Moapar(R) 11.25mg, the first 3-month injectable formulation, prescribed for a reversible reduction of serum testosterone to the level of castration in adult...

2009-07-14 06:45:00

MORRISTOWN, N.J., July 14 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that it received a Complete Response Letter from the U.S.

2009-05-18 08:30:00

Watson to Market and Sell Ferrlecit(R) through December 31, 2009 CORONA, Calif., May 18 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc.

2009-05-11 04:10:00

LAUSANNE and AESCH, Switzerland, May 11 /PRNewswire/ -- - 1- 3- and 6-Month Formulations - A new Treatment for Prostate Cancer Patients in Switzerland Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions, particularly in the field of oncology, and Mepha Pharma A.G.

2009-04-27 08:59:00

Trial Will Build on Pivotal Phase III Study for the Treatment of Advanced Prostate Cancer PARSIPPANY, N.J., April 27 /PRNewswire/ -- Ferring Pharmaceuticals announced today the launch of a Phase IIIB clinical trial of degarelix for injection, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S.

2008-12-24 16:52:00

New Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist Demonstrates Rapid, Long-term Suppression of Testosterone - a hormone that stimulates prostate cancer growth. PARSIPPANY, N.J., Dec. 24 /PRNewswire/ -- Ferring Pharmaceuticals, USA today received approval from the U.S.


Word of the Day
filiation
  • The relation of a son or daughter to a parent: the correlative of paternity.
  • The establishment of a filial relation, specifically by adoption.
  • In law, the judicial determination of the paternity of a child, especially of a bastard; affiliation.
The word 'filiation' comes from a Latin word meaning 'legal right of a son'.
Related